Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 49

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 49
---
872 | -11 |     |           | 1,279,038 |
|                                                        |     | 2023 |      |     |     | 444,000 |         |     |   947,500 |         |    |     |   514,593 |           |     |        177,600 |   |     |       13,779 |         |     |     | 2,097,472 |           |

| (1) | In accordance with SEC rules, these amounts reflect the grant date fair values of the RSUs granted in 2024, calculated in accordance with ASC Topic 718 for stock-based compensation transactions. The assumptions we used in valuing RSUs are described in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. |

| (2) | The amounts reflect the full grant date fair value for option awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation-Stock Compensation. Consistent with the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. |

| (3) | The amounts reflect the portion of each named executive officer’s target bonus earned based on the achievement of our corporate goals, which are discussed further below under “—Narrative to Summary Compensation Table—Annual Bonus.” |

| (4) | Dr. Rieger’s employment as our President and Chief Executive Officer began on November 6, 2024. Accordingly, Dr. Rieger was not a named executive officer for 2023 and, as a result, his compensation for that year has been omitted pursuant to applicable SEC rules and regulations. |

| (5) | Amount includes (a) 401(k) matching contributions of $13,800, (b) allowance for mobile phones of $600 and (c) life insurance premiums of $943. |

| (6) | Dr. Goldenberg was not a named executive officer for 2023 and, as a result, his compensation for that year has been omitted pursuant to applicable SEC rules